Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) 3-Year Book Growth Rate : -26.50% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals 3-Year Book Growth Rate?

Paradigm Biopharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was $0.06.

During the past 12 months, Paradigm Biopharmaceuticals's average Book Value per Share Growth Rate was -62.20% per year. During the past 3 years, the average Book Value per Share Growth Rate was -26.50% per year. During the past 5 years, the average Book Value per Share Growth Rate was -0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 8 years, the highest 3-Year average Book Value per Share Growth Rate of Paradigm Biopharmaceuticals was 55.40% per year. The lowest was -26.50% per year. And the median was 46.30% per year.

Competitive Comparison of Paradigm Biopharmaceuticals's 3-Year Book Growth Rate

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paradigm Biopharmaceuticals's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's 3-Year Book Growth Rate falls into.

Paradigm Biopharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Paradigm Biopharmaceuticals (OTCPK:PBIGF) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Paradigm Biopharmaceuticals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

PAR:Australia

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).